Americas Small Cap Research Summary

This report provides an update on C4 Therapeutics (CCCC), highlighting positive Phase 1 clinical data for cemsidomide presented at EHA. The analysts maintain an Overweight rating.

Key Takeaways

• 1.C4 Therapeutics' cemsidomide shows strong potential in Multiple Myeloma treatment due to deepening responses and MRD-negativity in heavily pre-treated patients.

Table of Contents

• Americas Small Cap Research Summary
• C4 Therapeutics: Updated Phase 1 Cemsidomide Data at EHA Continues to Highlight Cemsidomide's Differentiated Profile
• Analyst(s) Certification(s)
• Important Disclosures
• Availability of Disclosures
• Risk Disclosure(s)
• Guide to the Barclays Fundamental Equity Research Rating System
• Stock Rating
• Industry View
• Distribution of Ratings
• Guide to the Barclays Research Price Target
• Types of investment recommendations produced by Barclays Equity Research
• Disclosure of other investment recommendations produced by Barclays Equity Research
• Legal entities involved in producing Barclays Research
• Disclaimer
• Sustainable Investing Related Research
• IRS Circular 230 Prepared Materials Disclaimer